Roche Wins First FDA Approval for Obinutuzumab in Primary Membranous Nephropathy
Roche’s FDA approval of obinutuzumab brings the first disease‑specific therapy for primary membranous nephropathy, offering higher remission rates and earlier cure than standard care.
- CHUGAI PHARMACEUTICAL CO LTD
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
4 minutes to read






